Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Disclosure notice in Eurocine Vaccines

Eurocine Vaccines hereby announces that Flerie Invest AB has acquired shares in the company and holds above 10 % of the shares in the company. Flerie Invest AB holds approximately 12.55 % of the votes and capital. Further, Eurocine Vaccines announces that Formue Nord Markedsneutral A/S has decreased its holdings to approximately 3.09 % of the votes and capital.Flerie Invest AB has acquired approximately 12.55 % of the votes and capital in Eurocine Vaccines. Flerie Invest AB is an investment company within the biotechnology and life science sector with offices in Stockholm and London. The

Share repurchase update from Catena Media

From 13 September 2021 to 15 October 2021, Catena Media plc repurchased 1,504,810 of its ordinary shares as part of a share buyback programme initiated by the board of directors during the third quarter to promote more efficient capital usage by returning excess capital to shareholders. All repurchases were executed on Nasdaq Stockholm by Carnegie Investment Bank on behalf of Catena Media. The volume-weighted average price of these transactions during the period was SEK 57.65 per share. Following the repurchases and as of 15 October 2021, Catena Media holds 1,504,810, or 2 percent, of

Oncopeptides’ CFO Anders Martin-Löf will leave the company

STOCKHOLM — October 15, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that CFO Anders Martin-Löf has informed Oncopeptides that he will leave the company for personal reasons. Anders was appointed CFO in 2018 and has a six-month notice period. He will continue in his current role until a new temporary or permanent CFO takes office. A recruitment process will be initiated immediately.“Anders has been instrumental in the development of Oncopeptides from a R&

Nordax announces preliminary results of the recommended voluntary cash offer of NOK 105 per share in Bank Norwegian ASA

NOT FOR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA AND JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE PRIOR APPROVAL. FOR MORE INFORMATION ABOUT NORDAX'S VOLUNTARY OFFER, PLEASE SEE NORDAX'S FORMAL OFFER ANNOUNCEMENT, AVAILABLE AT: HTTPS://WWW.COLLABORATE-TO-SCALE.COM.Reference is made to the offer document dated 5 August 2021 (the "Offer Document") for the recommended voluntary offer by Nordax Bank AB (publ) ("Nordax" or the "Offeror") to acquire all outstanding shares in Bank Norwegian ASA (the "Company") against a consideration in cash

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 15.10.2021

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION 15.10.2021 at 18:30 EEST ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 15.10.2021 Date 15.10.2021Exchange transaction BuyShare class ALEXAmount 294Average price/share 8.1600 EURHighest price/share 8.1600 EURLowest price/share 8.1600 EURTotal price 2,399.04 EUR The shares held by Alexandria Pankkiiriliike Oyj on 15.10.2021: ALEX 32,457 On behalf of Alexandria Pankkiiriliike Oyj  Skandinaviska Enskilda Banken AB (Publ)

BICO completes the acquisition of QInstruments

As announced on October 1, 2021, BICO Group AB (publ) (“BICO”) entered into an agreement to acquire QInstruments GmbH. (“QInstruments”), a German company which is a leading developer, manufacturer, and supplier of advanced sample preparation automation by mixing solutions for liquid handling robots and workflows for biomedical and life science research and clinical diagnostics. BICO has on this day completed the acquisition of all QInstruments-shares. The preliminary purchase price for all shares amounted to approximately 61.25 million euro, which is subject to adjustment for net cash/

Settlement Notification by Nordax for the recommended voluntary cash offer of NOK 105 per share in Bank Norwegian ASA

NOT FOR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA AND JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE PRIOR APPROVAL. FOR MORE INFORMATION ABOUT NORDAX'S VOLUNTARY OFFER, PLEASE SEE NORDAX'S FORMAL OFFER ANNOUNCEMENT, AVAILABLE AT: HTTPS://WWW.COLLABORATE-TO-SCALE.COM.Reference is made to the offer document dated 5 August 2021 (the "Offer Document") for the recommended voluntary offer by Nordax Bank AB (publ) ("Nordax" or the "Offeror") to acquire all outstanding shares in Bank Norwegian ASA (the "Company") against a consideration in cash

DNB Markets - Episurf Medical: Financial position secured

Episurf Medical last night reported preliminary Q3 results as well as a capital raise of cSEK159m, which should secure its financial position into 2025, well past all important value inflection points regarding the EPIC Knee trial and potential 510(k) approval for the patellofemoral and MTP1-joint (big toe) implants in the US. We have updated our forecasts, and in turn lifted our fair value to SEK3.5–9.5 (previously SEK2.7–8.2).Q3 still affected by the pandemic. The company last night announced preliminary Q3 results. It said sales continued to be hurt by the pandemic and as a result should

Invitation to the Presentation of Alligator Bioscience´s Interim Report January - September 2021 on October 21, 2021

LUND (Sweden) – Alligator Bioscience will host a conference call (in English) investors, analysts and media on Thursday, October 21st, 2021, at 14:00 CET.  Alligator will publish the company's interim report on Thursday, October 21, 2021, at 8:00 CET. CEO, Søren Bregenholt and CFO, Marie Svensson will present the interim report for the period January - September 2021 Report followed by a Q&A session. The conference call will be broadcast live on the web and can be accessed via the link: https://financialhearings.com/event/13657 For more information, please contact: Julie

#21-339 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

BICO has been nominated for the Swedish Government’s Export Success of the Year 2020 Award

Today, the Swedish Government announced that the BICO Group is one of three companies nominated for the Export Success of the Year 2020 award. In an effort by the government to promote Swedish exports, the award honors companies that have made particularly meritorious efforts in inspiration and development. The award ceremony will take place at the Ministry for Foreign Affairs in Stockholm on October 22 and will be hosted by the Minister for Foreign Trade Anna Hallberg, as well as HRH Prince Daniel. "We are very honored by this nomination, and I am confident that our success is

SynAct Pharma doses first subject in study with new AP1189 tablets

SynAct Pharma AB (“SynAct”) today announced that the first subject has been dosed in a clinical study in healthy volunteers to describe the pharmacokinetics of AP1189 following administration of a new tablet formulation aimed for once daily dosing in further clinical development of the compound.The study is a single center, open label, 3-part pharmacokinetic study, with 12 healthy subjects in each part. The primary objective of the first part is to determine the relative bioavailability of AP1189 after dosing with the newly developed tablets versus the oral suspension used so far in

Isofol Medical AB (publ) intends to list its shares on Nasdaq Stockholm

GOTHENBURG, Sweden, October 15, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the “Company”), announced today that the Company intends to list its shares on Nasdaq Stockholm. Isofol’s shares are currently traded on Nasdaq First North Premier Growth Market under the ticker ISOFOL.Nasdaq Stockholm’s listing committee has made the assessment that Isofol fulfills the applicable listing requirements and will approve an application for admission to trading of the Company’s shares on Nasdaq Stockholm, provided that certain customary conditions

Componenta Castings Ltd has carried out payments required for premature ending of restructuring programme

Componenta Corporation, Stock Exchange Release, on 15 October 2021 at 16.10 pm Finnish time The Board of Directors of Componenta has on 13 October 2021 decided to end the Componenta Castings Ltd’s restructuring programme prematurely and to pay its restructuring debts in the total amount of approximately EUR 5.6 million. The Componenta Castings Ltd has on 15 October 2021 carried out the aforementioned payments of approximately EUR 5.6 million to its creditors, consisting of approximately EUR 3.4 million external restructuring debts and EUR 2.2 million intra-group restructuring debts.

Teollisuuden Voima Oyj Interim Report January–September 2021

During the first three quarters of 2021, Teollisuuden Voima’s (TVO) electricity generation at the Olkiluoto 1 (OL1) and Olkiluoto 2 (OL2) plant units continued safely and reliably.The fuel loading of the Olkiluoto 3 EPR plant unit (OL3 EPR) was completed in April 2021. Due to extended turbine overhaul and inspection works, the plant unit will be connected to the national grid in February 2022, and regular electricity production starts in June 2022 according to the updated schedule received from the plant supplier Areva−Siemens consortium in August 2021. The agreements regarding the

Endomines moves the execution date of the merger

Endomines AB (publ), Stock Exchange Release, 15.10.2021 at 15:00 CEST   Endomines moves the execution date of the merger  Endomines AB (publ) (the “Company”) announced on 3 June 2021 that the Company has decided on a down-stream cross-border merger (“Merger”) and re-domiciliation of the Company from Sweden to Finland.   On 21 September 2021, the Company informed that the execution of the Merger has been moved forward by two weeks to 18 October 2021.   Because of details related to the practicalities and various registrations of the Merger, the execution of the Merger is

A joint patent application for MALT1 inhibitors published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with Rheos Medicines, Inc., a US-based biopharmaceutical company, has been made public. The patent application is an outcome of the option agreement that was previously entered into between the two companies regarding Medivir’s preclinical MALT1 project. Neither target nor partner has previously been disclosed. Under the option agreement, Rheos has the right to evaluate Medivir’s MALT1 inhibitors in addition to its own internal work in this field.

British coffee shop chain chooses DUG

British company Gourmet Coffee Bar & Kitchen has in a short time established itself as the leading specialty coffee chain at the country’s railway stations. Now they choose to include DUG in their range of premium products.Gourmet Coffee Bar & Kitchen has around 60 expert baristas serving thousands of customers, commuters and others visiting British railway stations on a daily basis. From November, the range of milk alternatives will be expanded when the café chain can offer Veg of Lund’s plant-based drink DUG[®]. “With Gourmet we have partnered with a customer who has high ambitions

Northbaze Group is partnering up with Mudita.

Gothenburg October 15, 2021 - Northbaze Group AB, is partnering up with Mudita, a tech company based in Poland, to supply earphones and charging cables.Jays Headphones, a brand within Northbaze is continuing to venture into alternative channels apart from their regular branded sales channel. Jays Headphones has agreed to deliver earphones and charging cables to Mudita. The products will be bundled and sold separately within Muditas sales channels. Mudita is a polish tech company, with the mission to create high-quality products which put physical and mental well-being first. Thus far,

Akastor ASA: Invitation to presentation of third quarter results 2021

Akastor ASA invites investors and analysts to a webcast presentation of third quarter 2021 financial results on Friday 29 October 2021. Date and time: Friday 29 October 2021 at 8:00 CETPresenters: Karl Erik Kjelstad, Chief Executive Officer and Øyvind Paaske, Chief Financial Officer. The presentation will be held as a webcast: https://channel.royalcast.com/landingpage/hegnarmedia/20211029_4/ Questions can be submitted throughout the streaming event and the presentation material will be published at 07:00 CET on 29 October. The presentation will be available at www.akastor.

Eivor Andersson returning to the Board of First Camp Group AB

A high-profile name in the travel industry returns to the Board of First Camp. Eivor Andersson is now returning to the Board after a break.Eivor Andersson was elected Board member of First Camp Group AB in 2019, but left the Board in March 2021, in order to avoid a conflict of interest due to United Camping’s investment in Grönklittsgruppen AB (publ). In July 2021, United Camping acquired Svenska Campingpärlor AB, which was Grönklittsgruppen’s camping division with nine destinations in Sweden. Following United Camping’s divestment of its stake in Grönklittsgruppen, Eivor Andersson has

Major investment in Swedish production of advanced vaccines and biological drugs in Matfors

The Swedish investment company Flerie Invest has made a major investment to establish an innovation hub for advanced vaccines and biological drugs in Matfors in northern Sweden. The hub will provide Sweden with an infrastructure for process development and large-scale production in collaboration with innovative biotech companies.The establishment of the hub follows an acquisition of a subsidiary of the American company Charles River Laboratories Inc led by Flerie Invest. The new company will trade as NorthX Biologics. In addition to the $52m acquisition and further investment by Flerie

Eivor Andersson returning to the Board of First Camp Group AB

A high-profile name in the travel industry returns to the Board of First Camp. Eivor Andersson is now returning to the Board after a break.Eivor Andersson was elected Board member of First Camp Group AB in 2019, but left the Board in March 2021, in order to avoid a conflict of interest due to United Camping’s investment in Grönklittsgruppen AB (publ). In July 2021, United Camping acquired Svenska Campingpärlor AB, which was Grönklittsgruppen’s camping division with nine destinations in Sweden. Following United Camping’s divestment of its stake in Grönklittsgruppen, Eivor Andersson has

There are no items matching the current filter
There are no more items matching the current filter
Back to top